PT1742642E - Análogos de fosfonato de compostos inibidores da integrase do hiv - Google Patents

Análogos de fosfonato de compostos inibidores da integrase do hiv Download PDF

Info

Publication number
PT1742642E
PT1742642E PT05804767T PT05804767T PT1742642E PT 1742642 E PT1742642 E PT 1742642E PT 05804767 T PT05804767 T PT 05804767T PT 05804767 T PT05804767 T PT 05804767T PT 1742642 E PT1742642 E PT 1742642E
Authority
PT
Portugal
Prior art keywords
inhibitor compounds
integrase inhibitor
hiv integrase
phosphonate analogs
hiv
Prior art date
Application number
PT05804767T
Other languages
English (en)
Inventor
Choung U Kim
Zhenhong R Cai
Xiaowu Chen
Maria Fardis
Salman Y Jabri
Haolun Jin
Sanuel E Metobo
Richard M Pastor
Michael R Mish
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PT1742642E publication Critical patent/PT1742642E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548Phosphates or phosphonates, e.g. bone-seeking
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PT05804767T 2004-04-14 2005-04-11 Análogos de fosfonato de compostos inibidores da integrase do hiv PT1742642E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56267804P 2004-04-14 2004-04-14

Publications (1)

Publication Number Publication Date
PT1742642E true PT1742642E (pt) 2009-01-23

Family

ID=35276373

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05804767T PT1742642E (pt) 2004-04-14 2005-04-11 Análogos de fosfonato de compostos inibidores da integrase do hiv

Country Status (14)

Country Link
US (2) US20080076738A1 (pt)
EP (1) EP1742642B1 (pt)
JP (1) JP2007532665A (pt)
AT (1) ATE411030T1 (pt)
AU (1) AU2005249363A1 (pt)
CA (1) CA2562713A1 (pt)
DE (1) DE602005010413D1 (pt)
DK (1) DK1742642T3 (pt)
ES (1) ES2315922T3 (pt)
HK (1) HK1099235A1 (pt)
PL (1) PL1742642T3 (pt)
PT (1) PT1742642E (pt)
SI (1) SI1742642T1 (pt)
WO (1) WO2005117904A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035577A2 (en) * 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
US20070072831A1 (en) * 2005-05-16 2007-03-29 Gilead Sciences, Inc. Integrase inhibitor compounds
AU2006246930C1 (en) 2005-05-19 2012-01-19 Merck Canada Inc. Quinoline derivatives as EP4 antagonists
AU2006272521A1 (en) * 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of HIV
EP1987046A1 (en) * 2006-02-20 2008-11-05 Alembic Limited An improved process for the preparation of biphosphonic derivatives
US20090306054A1 (en) * 2006-05-16 2009-12-10 Gilead Sciences ,Inc. Integrase inhibitors
WO2009026206A1 (en) * 2007-08-21 2009-02-26 University Of Toledo Method for synthesizing xanthohumol
WO2009067541A2 (en) * 2007-11-20 2009-05-28 Gilead Sciences, Inc. Integrase inhibitors
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
SI2320908T1 (sl) * 2008-07-25 2014-05-30 Viiv Healthcare Company Predzdravila dolutegravirja
KR101772610B1 (ko) * 2008-07-25 2017-09-12 비이브 헬쓰케어 컴퍼니 화합물
WO2010068253A1 (en) 2008-12-11 2010-06-17 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
NZ627826A (en) * 2010-01-27 2016-01-29 Viiv Healthcare Co Antiviral combinations involving (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
TWI582097B (zh) 2010-03-23 2017-05-11 Viiv醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
US20120142701A1 (en) * 2010-05-28 2012-06-07 The University Of Hong Kong Compounds and methods for the treatment of proliferative diseases
WO2012031383A1 (zh) * 2010-09-06 2012-03-15 中国科学院广州生物医药与健康研究院 酰胺类化合物
JP5767393B2 (ja) 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
KR101365849B1 (ko) * 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
WO2016125048A1 (en) 2015-02-03 2016-08-11 Pfizer Inc. Novel cyclopropabenzofuranyl pyridopyrazinediones
JP6804790B1 (ja) 2017-12-07 2020-12-23 エモリー ユニバーシティー N4−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
WO2019113523A1 (en) 2017-12-08 2019-06-13 Ashok Bajji Compounds and therapeutic uses thereof
CN111484529A (zh) * 2019-01-28 2020-08-04 奥锐特药业股份有限公司 一种合成替诺福韦单苯酯的方法
CN112946154B (zh) * 2021-02-05 2022-10-25 石家庄四药有限公司 他汀类药物起始物料及其对映异构体的hplc检测方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH385846A (de) * 1960-03-31 1964-12-31 Geigy Ag J R Verfahren zur Herstellung von neuen 7-Acyl-8-hydroxy-chinolinen und ihre Verwendung als Fungizide und Bakterizide im Pflanzen- und Materialschutz
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DK0481214T3 (da) * 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
US5883255A (en) * 1990-10-31 1999-03-16 Smithkline Beecham Corporation Substituted indolizino 1,2-b!quinolinones
ATE156120T1 (de) * 1991-02-07 1997-08-15 Roussel Uclaf Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
EP0520573A1 (en) * 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives
US5639881A (en) * 1991-11-08 1997-06-17 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis and elucidation of pyrimido (4,5-Q) quinazoline derivatives
TW304945B (pt) * 1992-06-27 1997-05-11 Hoechst Ag
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
DK0736020T3 (da) * 1993-12-17 2000-08-07 Procter & Gamble 6-(2-imidazolinylamino)quinolinforbindelser, der er egnede som alfa-2-adrenoceptoragonister
US5538988A (en) * 1994-04-26 1996-07-23 Martinez; Gregory R. Benzocycloalkylazolethione derivatives
DE19613591A1 (de) * 1996-04-04 1997-10-09 Hoechst Ag Substituierte-Chinolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5854275A (en) * 1996-05-16 1998-12-29 Pfizer Inc. Cyclic imide derivatives
EP0927164A1 (en) * 1996-09-10 1999-07-07 PHARMACIA & UPJOHN COMPANY 8-hydroxy-7-substituted quinolines as anti-viral agents
DE19738005A1 (de) * 1997-08-30 1999-03-04 Bayer Ag Verwendung von substituierten 1,1-Bisphosphonaten
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
BR9911079A (pt) * 1998-06-10 2001-02-20 Arena Pharm Inc Acentuador de acetilcolina, composto, processo tanto para inibir a acetilcolina esterase de enzima quanto para antagonizar o receptor de serotonina 5ht3, e, composição farmacêutica.
CA2333643A1 (en) * 1998-06-30 2000-01-06 James D. Rodgers Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
US6187907B1 (en) * 1998-08-31 2001-02-13 James Chen Triple helix coil template having a biologically active ligand
AU3118200A (en) * 1998-12-14 2000-07-03 Merck & Co., Inc. Hiv integrase inhibitors
US6245806B1 (en) * 1999-08-03 2001-06-12 Merck & Co., Inc. HIV integrase inhibitors
AU8009900A (en) * 1999-10-13 2001-04-23 Merck & Co., Inc. Hiv integrase inhibitors
PE20011349A1 (es) * 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6525049B2 (en) * 2000-07-05 2003-02-25 Pharmacia & Upjohn Company Pyrroloquinolones as antiviral agents
AR036256A1 (es) * 2001-08-17 2004-08-25 Merck & Co Inc Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento
CN1313472C (zh) * 2002-04-26 2007-05-02 吉里德科学公司 Hiv蛋白酶抑制剂化合物的膦酸酯类似物的细胞蓄积及这类化合物
WO2004035577A2 (en) * 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds

Also Published As

Publication number Publication date
WO2005117904A2 (en) 2005-12-15
US20080076738A1 (en) 2008-03-27
EP1742642B1 (en) 2008-10-15
SI1742642T1 (sl) 2009-04-30
US20060116356A1 (en) 2006-06-01
WO2005117904A3 (en) 2006-07-27
AU2005249363A1 (en) 2005-12-15
HK1099235A1 (en) 2007-08-10
DE602005010413D1 (de) 2008-11-27
EP1742642A2 (en) 2007-01-17
DK1742642T3 (da) 2009-02-16
PL1742642T3 (pl) 2009-06-30
ES2315922T3 (es) 2009-04-01
JP2007532665A (ja) 2007-11-15
ATE411030T1 (de) 2008-10-15
CA2562713A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
HK1099235A1 (en) Phosphonate analogs of hiv integrase inhibitor compounds hiv
TW200716632A (en) Integrase inhibitor compounds
WO2004096128A3 (en) Hiv integrase inhibitors
WO2004004657A3 (en) Hiv integrase inhibitors
AP2412A (en) Phosphonate analogs of HIV inhibitor compounds.
TW200613289A (en) Prodrugs of hiv protease inhibitors
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
UA94833C2 (en) Substituted bicyclolactams
MX2009008275A (es) Formas polimorficas de un inhibidor macrociclico del virus de la hepatitis c.
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
MX2009011370A (es) Proceso para el intermediario del inhibidor proteasa de hcv.
WO2006028958A3 (en) Pyridyl inhibitors of hedgehog signalling
MX2009009920A (es) Inhibidores no nucleosidos de transcriptasa inversa.
WO2007136714A3 (en) Integrase inhibitors
TNSN08191A1 (en) Kinase inhibitors
SE0400284D0 (sv) Novel compounds
HK1148753A1 (en) Novel inhibitors of chymase
ATE404536T1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
HK1159614A1 (en) Caspase inhibitors and uses thereof
MX2010006397A (es) Compuestos heterociclicos antivirales.
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
TW200640912A (en) Novel processes for the preparation of a 2H-chromene
BR0315705A (pt) Inibidores de fosfodiesterase-4
TW200637539A (en) CTGF inhibitors
WO2009067541A3 (en) Integrase inhibitors